Provided by Tiger Fintech (Singapore) Pte. Ltd.

Compass Therapeutics, Inc.

3.48
+0.03501.02%
Volume:24.64K
Turnover:84.37K
Market Cap:596.21M
PE:-7.73
High:3.48
Open:3.42
Low:3.40
Close:3.44
52wk High:4.08
52wk Low:1.27
Shares:171.57M
Float Shares:123.05M
Volume Ratio:5.15
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4496
EPS(LYR):-0.3594
ROE:-51.84%
ROA:-31.14%
PB:6.40
PE(LYR):-9.67

Loading ...

Company Profile

Company Name:
Compass Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
35
Office Location:
80 Guest Street,Suite 601,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.